Posts tagged paediatric indication
Ladenburg starts Bellicum Pharma at buy

Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29.

Read More
Tandem expands pediatric indication of insulin pump

Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older.

The t:slim Pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the current t:slim pump features, with no changes to the existing user interface.

Read More